変形性関節症治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Osteoarthritis - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0861
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:345
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Osteoarthritis – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis – Pipeline Review, H1 2020, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.

Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 7, 22, 22, 1, 47 and 12 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 6 and 7 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Osteoarthritis – Overview
Osteoarthritis – Therapeutics Development
Osteoarthritis – Therapeutics Assessment
Osteoarthritis – Companies Involved in Therapeutics Development
Osteoarthritis – Drug Profiles
Osteoarthritis – Dormant Projects
Osteoarthritis – Discontinued Products
Osteoarthritis – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Osteoarthritis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Osteoarthritis - Pipeline by 4P-Pharma SAS, H1 2020
Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2020
Osteoarthritis - Pipeline by Ablynx NV, H1 2020
Osteoarthritis - Pipeline by Aclaris Therapeutics Inc, H1 2020
Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2020
Osteoarthritis - Dormant Projects, H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..3), H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..4), H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..5), H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..6), H1 2020
Osteoarthritis - Dormant Projects, H1 2020 (Contd..7), H1 2020
Osteoarthritis - Discontinued Products, H1 2020
Osteoarthritis - Discontinued Products, H1 2020 (Contd..1), H1 2020

【掲載企業】

4P-Pharma SAS
Abiogen Pharma SpA
Ablynx NV
Aclaris Therapeutics Inc
Akaal Pharma Pty Ltd
AKL Research and Development Ltd
Algomedix Inc
Amgen Inc
Amplicore Inc
Amzell BV
Arthrogen BV
Asta Pharmaceuticals Co Ltd
Atlanthera
Aurealis Pharma AG
Axsome Therapeutics Inc
Bioiberica SAU
Bioorg3.14 LLC
Bone Therapeutics SA
BRIM Biotechnology Inc
CAR-T (Shanghai) Biotechnology Co Ltd
Cellular Biomedicine Group Inc
Chondrogenix Ltd
Chugai Pharmaceutical Co Ltd
Cocoon Biotech, Inc.
Corestem Inc
Cynata Therapeutics Ltd
Cytonics Corp
Daewoong Pharmaceutical Co Ltd
DNX Biopharmaceuticals Inc
Eli Lilly and Co
EnhanX Biopharm Inc
Ensol Biosciences Inc
Eternity Bioscience Inc
Evgen Pharma Plc
Flexion Therapeutics Inc
Galapagos NV
GeneFrontier Corp
Genequine Biotherapeutics GmbH
General Regeneratives Shanghai Ltd
Gwoxi Stem Cell Applied Technology Co Ltd
Histogen Inc
HSRx Group
Inception Therapeutics Inc
InKemia IUCT Group SA
International Stem Cell Corp
K-Stemcell Co Ltd
Kang Stem Biotech Co Ltd
Kolon TissueGene Inc
Kukje Pharmaceutical Industry Co Ltd
Lateral Pharma Pty Ltd
Levolta Pharmaceuticals Inc
LG Chem Ltd
Link Health Group
Lubris Biopharma
Luye Pharma Group Ltd
Magellan Biologicals Pty Ltd
MediPost Co Ltd
Medivir AB
Merck KGaA
Mesoblast Ltd
MetrioPharm AG
Mor Research Applications Ltd
NeuroBo Pharmaceuticals Inc
New York R&D Center for Translational Medicine and Therapeutics Inc
Nordic Bioscience AS
Novartis AG
Orbis Biosciences Inc
Orbsen Therapeutics Ltd
OrthoTrophix Inc
Paradigm Biopharmaceuticals Ltd
Peptinov SAS
Personalized Stem Cells Inc
Pfizer Inc
Philogen SpA
PhytoHealth Corp
Plakous Therapeutics Inc
Progenitor Therapeutics Ltd
ProteoThera Inc
Regeneus Ltd
Regenosine Inc
Regulaxis SAS
Ribomic Inc
Rottapharm Biotech Srl
Samumed LLC
Seikagaku Corp
Serene LLC
SL Bigen Inc
Steminent Biotherapeutics Inc
Stempeutics Research Pvt Ltd
Synerkine Pharma BV
Synokem Pharmaceuticals Ltd
Taiwan Bio Therapeutics Co Ltd
Traverse Biosciences Inc
Unicocell Biomed Co Ltd
Unity Biotechnology Inc
WEX Pharmaceuticals Inc
Xalud Therapeutics Inc
Xintela AB
Yooyoung Pharm Co Ltd
Zimmer Biomet Holdings Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[変形性関節症治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆